Greenwich LifeSciences (GLSI) Change in Accured Expenses (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Change in Accured Expenses of $236620.0 for Q4 2025, up 90.85% on a QoQ basis from $123982.0 in Q3 2025, and down 14.5% year-over-year from $276745.0 in Q4 2024.
Greenwich LifeSciences (GLSI) Change in Accured Expenses (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $236620.0 for Q4 2025.
- Quarterly Change in Accured Expenses fell 14.5% year-over-year to $236620.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $367538.0 (up 20.0% YoY) and the FY2025 annual result came in at $367538.0, up 20.0% from the prior year.
- Change in Accured Expenses was $236620.0 for Q4 2025 at Greenwich LifeSciences, up from $123982.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $276745.0 in Q4 2024 and bottomed at -$144004.0 in Q1 2022.
- A 5-year average of $29209.4 and a median of $6693.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 3313.66% — and 2024, when it surged 1078.04%.
- Greenwich LifeSciences' Change in Accured Expenses stood at -$63301.0 in 2021, then surged by 139.53% to $25026.0 in 2022, then plunged by 213.07% to -$28296.0 in 2023, then jumped by 1078.04% to $276745.0 in 2024, then retreated by 14.5% to $236620.0 in 2025.
- Business Quant data shows GLSI's Change in Accured Expenses at $236620.0 in Q4 2025, $123982.0 in Q3 2025, and -$1510.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 236,620.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 236,620.00 |
| Dec 31, 2025 | 236,620.00 |
| Sep 30, 2025 | 123,982.00 |
| Sep 30, 2025 | 123,982.00 |
| Jun 30, 2025 | -1,510.00 |
| Jun 30, 2025 | -1,510.00 |
| Mar 31, 2025 | 8,446.00 |
| Mar 31, 2025 | 8,446.00 |
| Dec 31, 2024 | 276,745.00 |
| Dec 31, 2024 | 276,745.00 |
| Sep 30, 2024 | 49,828.00 |
| Sep 30, 2024 | 49,828.00 |
| Jun 30, 2024 | -25,232.00 |
| Jun 30, 2024 | -25,232.00 |
| Mar 31, 2024 | 4,940.00 |
| Mar 31, 2024 | 4,940.00 |
| Dec 31, 2023 | -28,296.00 |
| Dec 31, 2023 | -28,296.00 |
| Sep 30, 2023 | 65,302.00 |
| Sep 30, 2023 | 65,302.00 |